Trial reportEuropean urology2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
Trial report in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01235962 (A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.European urology · 2024Trial
- RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.Contemporary clinical trials · 2021Trial
- Renal Cell Carcinoma in the Geriatric Population: Toward a Frailty-Adapted Therapeutic Paradigm.Journal of clinical medicine · 2026Review
- A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.Annals of surgical oncology · 2026Article
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
- Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition.Frontiers in immunology · 2026Review
- Adjuvant therapy in chromophobe renal cell carcinoma: current evidence and unmet needs.Frontiers in oncology · 2026Review
- Advances in Adjuvant Therapy for Renal Cell Carcinoma: Perspectives on Risk Stratification and Treatment Outcomes.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- Perioperative therapies for metastatic renal cell carcinoma.Journal of cancer metastasis and treatment · 2025Article
- Adjuvant therapy in renal cell carcinoma (RCC): progress, at last.Translational cancer research · 2024Review
- Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.Journal of cancer research and clinical oncology · 2024Review
- A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma.BMC urology · 2024Review
- Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic.Research and reports in urology · 2024Article
- Outcomes and complications of hemodialysis in patients with renal cancer following bilateral nephrectomy.Open medicine (Warsaw, Poland) · 2024Article
- Perioperative systemic treatments in renal cell carcinoma.Frontiers in oncology · 2024Review
- The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.Human vaccines & immunotherapeutics · 2023Review
- Treatment Landscape of Renal Cell Carcinoma.Current treatment options in oncology · 2023Review
- Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 20 institutions in 11 countries.
Funding
Abstract
Most studies indicate no benefit of adjuvant therapy with VEGFR tyrosine kinase inhibitors in advanced renal cell carcinoma (RCC). PROTECT (NCT01235962) was a randomized, double-blind, placebo-controlled phase 3 study to evaluate adjuvant pazopanib in patients with locally advanced RCC at high risk of relapse after nephrectomy (pazopanib, n = 769; placebo, n = 769). The results of the primary analysis showed no difference in disease-free survival between pazopanib 600 mg and placebo. Here we report the final overall survival (OS) analysis (median follow-up: pazopanib, 76 mo, interquartile range [IQR] 66-84; placebo, 77 mo, IQR 69-85). There was no significant difference in OS between the pazopanib and placebo arms (hazard ratio 1.0, 95% confidence interval 0.80-1.26; nominal p > 0.9). OS was worse for patients with T4 disease compared to those with less advanced disease and was better for patients with body mass index (BMI) ≥30 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.